UUD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Very Low LeverageA debt-free balance sheet reduces interest burdens and refinancing exposure, preserving financial flexibility while the company develops its business. Low leverage also provides greater capacity to withstand operating volatility than a similarly loss-making company carrying substantial borrowings.
Substantial Equity BaseThe sizable equity base provides a meaningful capital cushion relative to reported assets and limits balance-sheet leverage. This supports near-term solvency and gives management more flexibility to fund operations or strategic activity without relying primarily on debt financing.
Historical Gross ProfitabilityThe historical gross margin indicates that the business generated meaningful gross profitability during periods with revenue, suggesting the underlying offering has previously supported attractive economics before operating costs. Re-establishing revenue could therefore provide operating leverage if costs are controlled.
Bears Say
No Recent RevenueThe absence of recorded revenue in the two latest fiscal years leaves the company without a demonstrated current commercial base. This weakens revenue visibility, limits operating leverage, and makes future performance dependent on successfully restoring meaningful sales activity.
Persistent Net LossesContinuing and worsening net losses show that the current business is not yet converting its resources into shareholder returns. Persistent losses can erode the equity base over time and reduce the company’s ability to reinvest, absorb setbacks, or achieve sustainable profitability.
Ongoing Cash BurnMaterially negative operating and free cash flow indicates that ongoing activities consume cash rather than fund themselves. Continued burn increases dependence on existing liquidity or external funding and can constrain strategic execution unless revenue generation or cost discipline improves.
Syntara Limited News
UUD FAQ
What was Pharmaxis Ltd’s price range in the past 12 months?
Currently, no data Available
What is Pharmaxis Ltd’s market cap?
Pharmaxis Ltd’s market cap is CHF28.77M.
When is Pharmaxis Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pharmaxis Ltd’s earnings last quarter?
Currently, no data Available
Is Pharmaxis Ltd overvalued?
According to Wall Street analysts Pharmaxis Ltd’s price is currently Undervalued.
Does Pharmaxis Ltd pay dividends?
Pharmaxis Ltd does not currently pay dividends.
What is Pharmaxis Ltd’s EPS estimate?
Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaxis Ltd have?
Currently, no data Available
What happened to Pharmaxis Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pharmaxis Ltd?
Currently, no hedge funds are holding shares in CH:UUD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Syntara Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF0.06 (― Upside)
CHF0.06 (― Upside)
Blogger Sentiment
Bullish
CH:UUD Sentiment 87%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pharmaxis Ltd
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
UUD Stock 12 Month Forecast
Average Price Target
―Elixinol Wellness
―
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―